KYTX - Kyverna Therapeutics, Inc. Common Stock

KYTX - Kyverna Therapeutics, Inc. Common Stock

https://kyvernatx.com

Recent News

Powered by Alpha Vantage

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026 - Kyverna Therapeutics ( NASDAQ:KYTX )

Benzinga • 3 weeks, 4 days ago • score: 0.33

Kyverna ended Q2 2025 with $211.7 million in cash, funding operations into 2027. Phase 3 KYV-101 trial in myasthenia gravis will begin by year-end 2025. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Kyverna Therapeutics ( NASDAQ:KYTX )

Benzinga • 3 months, 2 weeks ago • score: 0.24

Kyverna ended Q1 2025 with $242.6 million in cash, expected to fund operations into 2027. Phase 2 MG data is expected in H2 2025; SPS trial topline data is due by mid-2026. Unlock your all-in-one trading dashboard with real-time alerts, rankings, and stock ideas-now 60% off for Memorial Day.

This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Commercial Metals ( NYSE:CMC ) , BellRing Brands ( NYSE:BRBR )

Benzinga • 3 months, 2 weeks ago • score: 0.30

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Mitchell Kapoor upgraded Kyverna Therapeutics, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$7.85

52W Low

$1.78

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

3341.48

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.92

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

12.03%

Institutions (25–75% balanced)

62.34%

Shares Outstanding

43,245,700

Float

22,471,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-135,924,992

EPS (TTM)

-3.68

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.50%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—